Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alvotech SA ALVO

Healthcare Biotechnology
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating... see more

Recent & Breaking News (NDAQ:ALVO)

Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®

GlobeNewswire November 14, 2022

Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference

GlobeNewswire November 10, 2022

Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022

GlobeNewswire October 27, 2022

Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November

GlobeNewswire October 26, 2022

Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care

GlobeNewswire October 19, 2022

Alvotech's Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan

GlobeNewswire October 17, 2022

Alvotech Appoints Sarah Tanksley as Chief Quality Officer

GlobeNewswire October 11, 2022

Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®

GlobeNewswire September 22, 2022

Alvotech Reports Update on Initial AVT02 Biologics License Application

GlobeNewswire September 5, 2022

Alvotech Reports First Half 2022 Financial Results and Business Update

GlobeNewswire August 31, 2022

Alvotech Announces Corporate Sustainability Participation and Discloses ESG Data covering 2020 and 2021

GlobeNewswire August 29, 2022

Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

GlobeNewswire August 25, 2022

Alvotech to Participate in Two Upcoming Investor Conferences in September 2022

GlobeNewswire August 24, 2022

Alvotech to Report First Six Months and Second Quarter 2022 Financial Results on August 31, 2022 and Host Business Update Conference Call at 8:00 am ET on September 1, 2022

GlobeNewswire August 15, 2022

Alvotech's Board of Directors Approves Plan to Prepare for Listing on Nasdaq Main Market in Iceland

GlobeNewswire August 12, 2022

Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

GlobeNewswire July 20, 2022

Alvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded Company

GlobeNewswire July 14, 2022

Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®

GlobeNewswire July 7, 2022

Alvotech Debuts on NASDAQ First North Growth Market Becoming First Dual-Listed Icelandic Company in United States and Iceland

GlobeNewswire June 22, 2022